CN112888441A - B细胞恶性肿瘤的治疗 - Google Patents

B细胞恶性肿瘤的治疗 Download PDF

Info

Publication number
CN112888441A
CN112888441A CN201980067607.2A CN201980067607A CN112888441A CN 112888441 A CN112888441 A CN 112888441A CN 201980067607 A CN201980067607 A CN 201980067607A CN 112888441 A CN112888441 A CN 112888441A
Authority
CN
China
Prior art keywords
mixture
compound
alkyl
heterocyclyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067607.2A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·P·戈尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CN112888441A publication Critical patent/CN112888441A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980067607.2A 2018-08-14 2019-08-13 B细胞恶性肿瘤的治疗 Pending CN112888441A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US62/718,929 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US62/775,797 2018-12-05
US201962836511P 2019-04-19 2019-04-19
US62/836,511 2019-04-19
PCT/US2019/046411 WO2020036999A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Publications (1)

Publication Number Publication Date
CN112888441A true CN112888441A (zh) 2021-06-01

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067607.2A Pending CN112888441A (zh) 2018-08-14 2019-08-13 B细胞恶性肿瘤的治疗

Country Status (14)

Country Link
US (1) US20210299134A1 (enExample)
EP (1) EP3836935A4 (enExample)
JP (1) JP2021534115A (enExample)
KR (1) KR20210043635A (enExample)
CN (1) CN112888441A (enExample)
AU (1) AU2019321432A1 (enExample)
BR (1) BR112021002760A2 (enExample)
CA (1) CA3109184A1 (enExample)
IL (1) IL280726A (enExample)
MA (1) MA53236A (enExample)
MX (1) MX2021001606A (enExample)
SG (1) SG11202101450VA (enExample)
TW (1) TW202021591A (enExample)
WO (1) WO2020036999A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2018053437A1 (en) * 2016-09-19 2018-03-22 Mei Pharma, Inc. Combination therapy
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11365252B2 (en) * 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2018053437A1 (en) * 2016-09-19 2018-03-22 Mei Pharma, Inc. Combination therapy
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用

Also Published As

Publication number Publication date
JP2021534115A (ja) 2021-12-09
CA3109184A1 (en) 2020-02-20
IL280726A (en) 2021-03-25
SG11202101450VA (en) 2021-03-30
TW202021591A (zh) 2020-06-16
EP3836935A1 (en) 2021-06-23
US20210299134A1 (en) 2021-09-30
EP3836935A4 (en) 2022-09-14
MX2021001606A (es) 2021-04-19
KR20210043635A (ko) 2021-04-21
BR112021002760A2 (pt) 2021-05-11
WO2020036999A1 (en) 2020-02-20
MA53236A (fr) 2021-06-23
AU2019321432A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
KR102736865B1 (ko) 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
CN107108637B (zh) 三唑并嘧啶化合物及其用途
CN106660991B (zh) 抗增殖化合物及其使用方法
JP6404332B2 (ja) 新規な、ＮＩＫ阻害剤としての３−（１Ｈ−ピラゾール−４−イル）−１Ｈ−ピロロ［２，３−ｃ］ピリジン誘導体
JP2026001008A (ja) Ｂｒｄ９の標的分解のための化合物
CN112165939A (zh) 联合疗法
JP6616411B2 (ja) 新規な、ｎｉｋ阻害剤としてのピラゾール誘導体
JP6616412B2 (ja) Ｎｉｋ阻害剤としての新規のピラゾロピリミジン誘導体
JP2017531681A (ja) Ｎｉｋ阻害剤としての新規化合物
US12428420B2 (en) Tricyclic heterocycles as FGFR inhibitors
CN112739420A (zh) 苯氧基-吡啶基-嘧啶化合物及使用方法
TW201924679A (zh) 抗腫瘤劑
KR20200041358A (ko) 병용 요법
JP2025538228A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
KR20210043635A (ko) B 세포 악성 종양의 치료
CN112839659A (zh) 复发性滤泡性淋巴瘤的治疗
CN112839651A (zh) 联合疗法
WO2020198067A1 (en) Pkm2 modulators and methods for their use
CN118891255A (zh) 新化合物及其抑制检查点激酶2的用途
JP2025502326A (ja) デオキシシチジンキナーゼ阻害剤
HK40051446A (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210601